



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/807,827	03/24/2004	Keith R. Hildebrand	P-20905.00US	4308
27581	7590	11/30/2005	EXAMINER	
MEDTRONIC, INC. 710 MEDTRONIC PARK MINNEAPOLIS, MN 55432-9924			STITZEL, DAVID PAUL	
			ART UNIT	PAPER NUMBER
			1616	
DATE MAILED: 11/30/2005				

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary	Application No. 10/807,827	Applicant(s) HILDEBRAND ET AL.	
	Examiner David P. Stitzel, Esq.	Art Unit 1616	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --
Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☐ Responsive to communication(s) filed on ____.
- 2a) ☐ This action is **FINAL**. 2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 1-28,58 and 59 is/are pending in the application.
 4a) Of the above claim(s) 29-57 is/are withdrawn from consideration.
- 5) ☐ Claim(s) ____ is/are allowed.
- 6) ☐ Claim(s) 1-28,58 and 59 is/are rejected.
- 7) ☐ Claim(s) ____ is/are objected to.
- 8) ☐ Claim(s) ____ are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on ____ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
 Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
 Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
 a) ☐ All b) ☐ Some * c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
 2. ☐ Certified copies of the priority documents have been received in Application No. ____.
 3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).
- * See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- | | |
|---|--|
| 1) <input checked="" type="checkbox"/> Notice of References Cited (PTO-892) | 4) <input type="checkbox"/> Interview Summary (PTO-413)
Paper No(s)/Mail Date. ____ |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948) | 5) <input type="checkbox"/> Notice of Informal Patent Application (PTO-152) |
| 3) <input type="checkbox"/> Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08)
Paper No(s)/Mail Date ____ | 6) <input type="checkbox"/> Other: ____ |

OFFICIAL ACTION

Restriction/Election

Restriction to one of the following inventions is required under 35 U.S.C. § 121:

- I. Claims 1-28 and 58-59 are drawn to a system for delivering to cerebrospinal fluid or brain tissue an injectable pharmaceutical composition in a therapeutically effective amount sufficient to treat epilepsy.
- II. Claims 29-57 are drawn to a method of treating epilepsy by administering a therapeutically effective amount of an injectable pharmaceutical composition to cerebrospinal fluid or brain tissue via a system.

Inventions I and II are related as a product and a method of using said product. The inventions can be shown to be distinct if either or both of the following can be shown that: (1) the method of using the product as claimed can be practiced with another materially different product; or (2) the product as claimed can be used by another method that is materially different from the instantly claimed method of using said product (MPEP § 806.05(f)). In the instant case, the system as claimed in Invention I can be used by another method that is materially different from the method claimed in Invention II. For example, as opposed to using said system for delivering to cerebrospinal fluid or brain tissue an injectable pharmaceutical composition comprising gabapentin in a therapeutically effective amount sufficient to treat epilepsy, said system may alternatively be used for delivering to cerebrospinal fluid or brain tissue an injectable pharmaceutical composition comprising gabapentin in a therapeutically effective amount sufficient to treat pain.

Because these inventions are distinct for the reasons given above and the search required for Group I is not required for Group II, restriction for examination purposes as indicated is proper.

Conclusion to Restriction Requirement

The Examiner has required restriction between product and methods of making claims. Where Applicant elects claims directed to the product, and a product claim is subsequently found allowable, withdrawn methods of making claims that depend from or otherwise include all the limitations of the allowable product claim will be rejoined in accordance with the provisions of MPEP § 821.04. Methods of making claims that depend from or otherwise include all the limitations of the patentable product will be entered as a matter of right if the amendment is presented prior to final rejection or allowance, whichever is earlier. If claims are added after the election, Applicants must explicitly indicate which claims are readable upon the elected species. See MPEP § 809.02(a). Amendments submitted after final rejection are governed by 37 CFR 1.116. Amendments submitted after allowance are governed by 37 CFR 1.312.

In the event of rejoinder, the requirement for restriction between the product claims and the rejoined methods of making claims will be withdrawn, and the rejoined methods of making claims will be fully examined for patentability in accordance with 37 CFR 1.104. Thus, to be allowable, the rejoined claims must meet all criteria for patentability including the requirements of 35 U.S.C. §§ 101, 102, 103 and 112. Until an elected product claim is found allowable, an otherwise proper restriction requirement between product claims and methods of making claims may be maintained. Withdrawn methods of making claims that are not commensurate in scope with an allowed product claim will not be rejoined. See “Guidance on Treatment of Product and Process Claims in light of *In re Ochiai*, *In re Brouwer* and 35 U.S.C. § 103(b),” 1184 O.G. 86 (March 26, 1996). Additionally, in order to retain the right to rejoinder in accordance with the above policy, Applicant is advised that the methods of making claims should be amended during prosecution either to maintain dependency on the product claims or

to otherwise include the limitations of the product claims. Failure to do so may result in a loss of the right to rejoinder. Further, note that the prohibition against double patenting rejections of 35 U.S.C. § 121 does not apply where the restriction requirement is withdrawn by the Examiner before the patent issues. See MPEP § 804.01.

Applicants are reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR § 1.48(b) if one or more of the currently named Inventors is no longer an actual Inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR § 1.48(b) and by the fee required under 37 CFR § 1.17(i).

During a telephone conversation with Mr. Keith M. Campbell, Esq. on Tuesday, November 16, 2005, at approximately 5:15 P.M., a provisional election was made *without traverse* to prosecute the Invention of Group I, claims 1-28 and 58-59. As a result and pursuant to 37 CFR § 1.142(b), claims 29-57 are withdrawn from further consideration as being drawn to a non-elected invention.

Status of Claims

As previously discussed, claims 29-57 are withdrawn from further consideration as being drawn to a non-elected invention. On the other hand, claims 1-28 and 58-59 are drawn to the elected Invention of Group I. As a result, claims 1-28 and 58-59 are currently pending and therefore examined herein on the merits for patentability.

Claim Rejections - 35 U.S.C. § 112, Second Paragraph

The following is a quotation of the second paragraph of 35 U.S.C. § 112, which forms the basis of the claim rejection as set forth under this particular section of the Official Action:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

Claim 6 is rejected under 35 U.S.C. § 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which Applicant regards as the invention. More specifically, the phrase “comprises between about 30 mg/ml gabapentin” renders said claim indefinite because the meets and bounds of said claim is unclear, as confusion exists with respect to the intended scope of said claim. That is, the claim recitation “between” indicates that the concentration of gabapentin lies within a range between two specific enumerated concentrations, however only a single concentration is expressly set forth. Therefore, Applicants are required to either remove the claim recitation “between,” or explicitly delineate a second specific concentration of gabapentin, other than 30 mg/ml, thereby setting forth the upper or lower limit of gabapentin concentration within the claimed range. See MPEP § 2173.05(d).

Provisional Nonstatutory Double Patenting

A nonstatutory double patenting rejection of the “obviousness-type” is based on a judicially created doctrine grounded in public policy so as to prevent not only the unjustified or improper timewise extension of the “right to exclude” granted by a patent, but also possible harassment by multiple assignees. See *In re Goodman*, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); *In re Longi*, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); *In re Van Ornum*, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); *In re Vogel*, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); *In re Thorington*, 418 F.2d 528, 163 USPQ 644 (CCPA 1969); *In re White*, 405 F.2d 904, 160 USPQ 417 (CCPA 1969); *In re Schneller*, 397 F.2d 350, 158 USPQ 210 (CCPA 1968); and *In re Sarett*, 327 F.2d 1005, 140 USPQ 474 (CCPA 1964).

A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) may be used to overcome an actual or provisional rejection based on a nonstatutory double patenting ground provided the conflicting application or patent is shown to be commonly owned or assigned with this application. See 37 CFR 1.130(b). Effective January 1, 1994, a registered attorney or agent of record may sign a terminal disclaimer. A terminal disclaimer signed by the assignee must fully comply with 37 CFR 3.73(b).

When considering whether the invention defined in a claim of an application is an obvious variation of the invention defined in the claim of a patent, the disclosure of the patent may not be used as prior art. See MPEP § 804. However, this does not mean that one is absolutely precluded from all use of the patent disclosure. See MPEP § 804. For example, the specification can always be used as a dictionary to learn the meaning of a term in the patent claim. *In re Boylan*, 392 F.2d 1017, 157 USPQ 370 (CCPA 1968). Furthermore, *those portions of the specification which provide support for the patent claims may also be examined and considered* when addressing the issue of whether a claim in the application defines an obvious variation of an invention claimed in the patent. *In re Vogel*, 422 F.2d 438, 441-442, 164 USPQ 619, 622 (CCPA 1970). The court in *Vogel* stated that one must first “determine how much of the patent disclosure pertains to the invention claimed in the patent” because only “[t]his portion of the specification supports the patent claims and may be considered.” The court in *Vogel* also pointed out that “this use of the disclosure is not in contravention of the cases forbidding its use as prior art, nor is it applying the patent as a reference under 35 U.S.C. § 103, since only the disclosure of the invention claimed in the patent may be examined.”

1. Claims 1-28 and 58-59 of the instant application (10/807827) are provisionally rejected under the judicially created doctrine of obviousness-type double patenting as being unpatentable over conflicting claims 1-29, 34-44 and 51 of copending U.S. Patent Application Serial Number (10/808129) (hereinafter the conflicting Hildebrand '129 application).

More specifically, claims 1-28 and 58-59 of the instant application are directed to a system comprising an implantable pump, which is coupled to a reservoir and a catheter, for intrathecal administration of an injectable pharmaceutical composition into cerebrospinal fluid, wherein said injectable pharmaceutical composition comprises an aqueous saline solution of gabapentin in combination with an additional therapeutic agent selected from the following: sodium valproate, midazolam and baclofen; wherein said gabapentin is present in said aqueous saline solution at a concentration of greater than about 30 mg/mL; wherein said baclofen is present in said aqueous saline solution at a concentration from about 50 µg/mL to about 3000 µg/mL; wherein said sodium valproate is present in said aqueous saline solution at a concentration from about 1 mg/mL to about 100 mg/mL; wherein said midazolam is present in said aqueous saline solution at a concentration from about 1 mg/mL to about 5 mg/mL; wherein said aqueous saline solution has a pH between about 4 and about 9; wherein said aqueous saline solution has a tonicity that is substantially isotonic with cerebrospinal fluid; wherein said aqueous saline solution is substantially free of preservatives and buffers.

Claims 1-29, 34-44 and 51 of the conflicting Hildebrand '129 application are directed to a sterilized injectable pharmaceutical composition comprising an aqueous saline solution of gabapentin in combination with an additional therapeutic agent selected from the following: sodium valproate, midazolam and baclofen; wherein said gabapentin is present in said aqueous saline solution at a concentration of greater than about 30 mg/mL; wherein said aqueous saline solution has a pH between

about 4 and about 9; wherein said aqueous saline solution has a tonicity of about 250 mOsm, which is substantially isotonic with cerebrospinal fluid; wherein said aqueous saline solution is substantially free of preservatives and buffers; wherein said sterilized injectable pharmaceutical composition is packaged within a kit that further comprises instructions.

Although the aforementioned claims of the conflicting Hildebrand '129 application do not explicitly recite the instantly claimed system comprising an implantable pump, which is coupled to a reservoir and a catheter, for intrathecal administration of an injectable pharmaceutical composition into cerebrospinal fluid, it would have been prima facie obvious to one of ordinary skill in the art at the time the instant application was filed to utilize a system comprising an implantable pump, which is coupled to a reservoir and a catheter, for intrathecal administration of an injectable pharmaceutical composition into cerebrospinal fluid, as the conflicting Hildebrand '129 application explicitly teaches utilizing a system comprising an implantable pump, which is coupled to a reservoir and a catheter, for intrathecal administration of an injectable pharmaceutical composition into cerebrospinal fluid ([0043]-[0048] and claim 37). Therefore, one of ordinary skill in the art would have been motivated to utilize a system comprising an implantable pump, which is coupled to a reservoir and a catheter, for intrathecal administration of an injectable pharmaceutical composition into cerebrospinal fluid.

With respect to claim 23 of the instant application, although the aforementioned claims of the conflicting Hildebrand '129 application do not explicitly recite the instantly claimed concentrations of baclofen, it would have been prima facie obvious to one of ordinary skill in the art at the time the instant application was filed to utilize baclofen at a concentration from about 50 µg/mL to about 3000 µg/mL within said aqueous saline solution, as the conflicting Hildebrand '129 application explicitly

teaches utilizing baclofen at a concentration from about 10 µg/mL to about 4000 µg/mL, and from about 50 µg/mL to about 2000 µg/mL, within said aqueous saline solution ([0037]-[0038]).

With respect to claims 25 and 27 of the instant application, although the aforementioned claims of the conflicting Hildebrand '129 application do not explicitly recite the instantly claimed concentrations of sodium valproate and midazolam, the conflicting Hildebrand '129 application does in fact teach that it would be readily recognized by those of ordinary skill in the art that any useful amount of sodium valproate and midazolam may be included within said injectable pharmaceutical composition comprising gabapentin ([0037]-[0038]). Suitable therapeutic dosages of sodium valproate and midazolam are readily obtainable by standard techniques well known to those of ordinary skill in the art. Furthermore, it is well within the purview of the skilled artisan to determine the desired optimal workable concentrations of sodium valproate and midazolam by systematically adjusting the injectable dosage amounts of sodium valproate and midazolam in a given per unit volume of diluent during the course of routine experimentation.

In conclusion, although claims 1-28 and 58-59 of the instant application are not identical to claims 1-29, 34-44 and 51 of the conflicting Hildebrand '129 application, the aforementioned claims are not patentably distinct each from the other because said claims are substantially overlapping in scope.

2. Claims 1-28 and 58-59 of the instant application (10/807827) are provisionally rejected under the judicially created doctrine of obviousness-type double patenting as being unpatentable over conflicting claims 1-27 and 51 of copending U.S. Patent Application Serial Number 10/807828 (hereinafter the conflicting Hildebrand '828 application).

More specifically, claims 1-28 and 58-59 of the instant application are directed to a system comprising an implantable pump, which is coupled to a reservoir and a catheter, for intrathecal administration of an injectable pharmaceutical composition into cerebrospinal fluid, wherein said injectable pharmaceutical composition comprises an aqueous saline solution of gabapentin in combination with an additional therapeutic agent selected from the following: sodium valproate, midazolam and baclofen; wherein said gabapentin is present in said aqueous saline solution at a concentration of greater than about 30 mg/mL; wherein said baclofen is present in said aqueous saline solution at a concentration from about 50 µg/mL to about 3000 µg/mL; wherein said sodium valproate is present in said aqueous saline solution at a concentration from about 1 mg/mL to about 100 mg/mL; wherein said midazolam is present in said aqueous saline solution at a concentration from about 1 mg/mL to about 5 mg/mL; wherein said aqueous saline solution has a pH between about 4 and about 9; wherein said aqueous saline solution has a tonicity that is substantially isotonic with cerebrospinal fluid; wherein said aqueous saline solution is substantially free of preservatives and buffers.

Claims 1-27 and 51 of the conflicting Hildebrand '828 application are directed to a system comprising an external or implantable pump, which is coupled to a reservoir and a catheter, for intrathecal administration of an injectable pharmaceutical composition into cerebrospinal fluid, wherein said injectable pharmaceutical composition comprises an aqueous saline solution of gabapentin in combination with an additional therapeutic agent selected from the following: a GABA agonist (i.e., valproic acid or sodium valproate) and baclofen; wherein said gabapentin is present in said aqueous saline solution at a concentration of greater than about 30 mg/mL; wherein said aqueous saline solution has a pH between about 4 and about 9; wherein said aqueous saline solution has a

tonicity that is substantially isotonic with cerebrospinal fluid; wherein said aqueous saline solution is substantially free of preservatives and buffers.

With respect to claim 23 of the instant application, although the aforementioned claims of the conflicting Hildebrand '828 application do not explicitly recite the instantly claimed concentrations of baclofen, it would have been prima facie obvious to one of ordinary skill in the art at the time the instant application was filed to utilize baclofen at a concentration from about 50 µg/mL to about 3000 µg/mL within said aqueous saline solution, as the conflicting Hildebrand '828 application explicitly teaches utilizing baclofen at a concentration from about 10 µg/mL to about 4000 µg/mL, and from about 50 µg/mL to about 2000 µg/mL, within said aqueous saline solution ([0048]).

With respect to claims 25 and 27 of the instant application, although the aforementioned claims of the conflicting Hildebrand '828 application do not explicitly recite the instantly claimed concentrations of sodium valproate and midazolam, not only would it have been prima facie obvious to one of ordinary skill in the art at the time the instant application was filed to utilize sodium valproate at a concentration from about 1 mg/mL to about 100 mg/mL within said aqueous saline solution, but it would also have been prima facie obvious to one of ordinary skill in the art at the time the instant application was filed to utilize midazolam at a concentration from about 1 mg/mL to about 5 mg/mL within said aqueous saline solution, as the conflicting Hildebrand '828 application explicitly teaches that said injectable pharmaceutical composition may further comprise a GABA agonist and an anticonvulsant ([0046] and [0048]). Sodium valproate, like valproic acid, is a GABA agonist. Midazolam, which is a derivative of the anticonvulsant diazepam, is also an anticonvulsant. Therefore, it would be readily recognized by those of ordinary skill in the art that any useful amount of sodium valproate and midazolam may be included within said injectable pharmaceutical composition

comprising gabapentin ([0046] and [0048]). Suitable therapeutic dosages of sodium valproate and midazolam are readily obtainable by standard techniques well known to those of ordinary skill in the art. Furthermore, it is well within the purview of the skilled artisan to determine the desired optimal workable concentrations of sodium valproate and midazolam by systematically adjusting the injectable dosage amounts of sodium valproate and midazolam in a given per unit volume of diluent during the course of routine experimentation.

In conclusion, although claims 1-28 and 58-59 of the instant application are not identical to claims 1-27 and 51 of the conflicting Hildebrand '828 application, the aforementioned claims are not patentably distinct each from the other because said claims are substantially overlapping in scope.

3. Claims 1-28 and 58-59 of the instant application (10/807827) are provisionally rejected under the judicially created doctrine of obviousness-type double patenting as being unpatentable over conflicting claims 1-48 of copending U.S. Patent Application Serial Number 10/808054 (hereinafter the conflicting Hildebrand '054 application).

More specifically, claims 1-28 and 58-59 of the instant application are directed to a system comprising an implantable pump, which is coupled to a reservoir and a catheter, for intrathecal administration of an injectable pharmaceutical composition into cerebrospinal fluid, wherein said injectable pharmaceutical composition comprises an aqueous saline solution of gabapentin in combination with an additional therapeutic agent selected from the following: sodium valproate, midazolam and baclofen; wherein said gabapentin is present in said aqueous saline solution at a concentration of greater than about 30 mg/mL; wherein said baclofen is present in said aqueous saline solution at a concentration from about 50 µg/mL to about 3000 µg/mL; wherein said sodium valproate

is present in said aqueous saline solution at a concentration from about 1 mg/mL to about 100 mg/mL; wherein said midazolam is present in said aqueous saline solution at a concentration from about 1 mg/mL to about 5 mg/mL; wherein said aqueous saline solution has a pH between about 4 and about 9; wherein said aqueous saline solution has a tonicity that is substantially isotonic with cerebrospinal fluid; wherein said aqueous saline solution is substantially free of preservatives and buffers.

Claims 1-48 of the conflicting Hildebrand '054 application are directed to a system comprising an implantable pump ([0047]-[0057]), which is coupled to a reservoir and a catheter, for intrathecal administration of an injectable pharmaceutical composition into cerebrospinal fluid, wherein said injectable pharmaceutical composition comprises an aqueous saline solution of gabapentin in combination with an additional therapeutic agent selected from the following: baclofen, sodium valproate and midazolam; wherein said gabapentin is present in said aqueous saline solution at a concentration of greater than about 30 mg/mL; wherein said aqueous saline solution has a pH between about 4 and about 9; wherein said aqueous saline solution has a tonicity that is substantially isotonic with cerebrospinal fluid; wherein said aqueous saline solution is substantially free of preservatives and buffers.

With respect to claim 23 of the instant application, although the aforementioned claims of the conflicting Hildebrand '054 application do not explicitly recite the instantly claimed concentrations of baclofen, it would have been prima facie obvious to one of ordinary skill in the art at the time the instant application was filed to utilize baclofen at a concentration from about 50 µg/mL to about 3000 µg/mL within said aqueous saline solution, as the conflicting Hildebrand '054 application explicitly teaches utilizing baclofen at a concentration from about 10 µg/mL to about 4000 µg/mL, and from about 50 µg/mL to about 2000 µg/mL, within said aqueous saline solution ([0038]-[0039]).

With respect to claims 25 and 27 of the instant application, although the aforementioned claims of the conflicting Hildebrand '054 application do not explicitly recite the instantly claimed concentrations of sodium valproate and midazolam, not only would it have been prima facie obvious to one of ordinary skill in the art at the time the instant application was filed to utilize sodium valproate at a concentration from about 1 mg/mL to about 100 mg/mL within said aqueous saline solution, but it would also have been prima facie obvious to one of ordinary skill in the art at the time the instant application was filed to utilize midazolam at a concentration from about 1 mg/mL to about 5 mg/mL within said aqueous saline solution, as the conflicting Hildebrand '054 application explicitly teaches that it would be readily recognized by those of ordinary skill in the art that any useful amount of sodium valproate and midazolam may be included within said injectable pharmaceutical composition comprising gabapentin ([0038]-[0039]). Suitable therapeutic dosages of sodium valproate and midazolam are readily obtainable by standard techniques well known to those of ordinary skill in the art. Furthermore, it is well within the purview of the skilled artisan to determine the desired optimal workable concentrations of sodium valproate and midazolam by systematically adjusting the injectable dosage amounts of sodium valproate and midazolam in a given per unit volume of diluent during the course of routine experimentation.

In conclusion, although claims 1-28 and 58-59 of the instant application are not identical to claims 1-48 of the conflicting Hildebrand '054 application, the aforementioned claims are not patentably distinct each from the other because said claims are substantially overlapping in scope.

Claim Rejections - 35 U.S.C. § 103

The following is a quotation of the appropriate paragraph of 35 U.S.C. § 103, which forms the basis of the obviousness rejections as set forth under this particular section of the Official Action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

1. Claims 1-28 and 58-59 are rejected under 35 U.S.C. § 103(a) as being unpatentable over U.S. Pre-Grant Patent Application Publication Number 2001/0036943 (hereinafter the Coe '943 publication) in view of U.S. Patent 6,495,601 (hereinafter the Hochman '601 patent).

With respect to claims 1-28 and 58-59 of the instant application, the Coe '943 publication teaches an injectable pharmaceutical composition ([0004], [0283], [0370] and [0372]), which may comprise: an anticonvulsant, such as gabapentin and valproic acid ([0006], [0138] and [0270]); an analgesic, such as baclofen ([0004], [0006] and [0270]); and a pharmaceutically acceptable carrier ([0004], [0006], [0368] and [0369]). Gabapentin may be present in an amount from 0.1% by weight to 95% by weight of said pharmaceutical composition ([0373]) and parenterally administered ([0283] and [0370]) in an amount from 10.0 mg/kg/day to 35.0 mg/kg/day ([0315]). Valproic acid may be present in an amount from 0.1% by weight to 95% by weight of said pharmaceutical composition ([0373]) and parenterally administered ([0283] and [0370]) in an amount from 1.0 mg/kg/day to 60.0 mg/kg/day ([0319]). Baclofen may be present in an amount from 0.1% by weight to 95% by weight of said pharmaceutical composition ([0373]) and parenterally administered ([0283] and [0370]) in an amount from 0.1 mg/kg/day to 0.5 mg/kg/day ([0315]). The pharmaceutically acceptable carrier is an aqueous isotonic saline solution ([0370]). In regard to claims 14-15 and 17 in particular, the Coe '943 publication is utterly devoid of any teachings of the utilization of preservatives and merely mentions that said sterile aqueous isotonic saline solution may be suitably buffered, if necessary, so as to render

said injectable pharmaceutical composition possessing an osmolality suitable for parenteral administration.

While the Coe '943 publication does not explicitly teach intracranial, intrathecal or epidural administration via a system comprising an implantable pump, which is coupled to a reservoir and a catheter, for intracranial, intrathecal or epidural administration of an injectable pharmaceutical composition into cerebrospinal fluid, the Coe '943 publication does in fact teach parenteral administration of said injectable pharmaceutical composition ([0283] and [0370]). However, the Hochman '601 patent teaches intracranial, intrathecal or epidural administration (column 12, lines 60-67; and column 14, lines 9-12) via a system comprising an implantable pump (column 7, lines 40-44; column 13, lines 23-33, 38-39 and 49-53; column 14, lines 51-52) for delivering to brain tissue via intracranial administration (column 12, lines 60-67), or cerebrospinal fluid via intrathecal or epidural administration (column 12, lines 60-67; column 13, lines 31-33; and column 14, lines 9-12), an injectable pharmaceutical composition comprising gabapentin, valproate and midazolam (column 14, lines 42-67; and column 15, lines 1-47) in a therapeutically effective amount sufficient to treat epilepsy and pain (column 6, lines 22-25; column 13, lines 58-60; column 14, lines 45-46 and 50; and column 15, lines 39-43). Therefore, it would have been prima facie obvious to one of ordinary skill in the art at the time the instant application was filed to administer said injectable pharmaceutical composition intracranially, intrathecally or epidurally via a system comprising an implantable osmotic pump, which is coupled to a reservoir and a catheter, as parenteral administration by definition includes any route of administration (i.e., intracranial, intrathecal or epidural) other than enteral (i.e., oral) administration. In addition, it would have been prima facie obvious to one of ordinary skill in the art at the time the instant application was filed to not only couple a therapeutic agent containing reservoir to said

implantable pump, but also couple a catheter to said implantable pump so as to provide a means for delivering said injectable pharmaceutical composition to brain tissue by intracranial administration, or cerebrospinal fluid by intrathecal or epidural administration, via said system. Furthermore, it would have also been prima facie obvious to one of ordinary skill in the art at the time the instant application was filed to incorporate the injectable pharmaceutical composition, of the Coe '943 publication, into a system comprising an implantable pump having a therapeutic agent containing reservoir and a catheter coupled to said implantable osmotic pump so as to provide a means for delivering said injectable pharmaceutical composition to brain tissue by intracranial administration, or cerebrospinal fluid by intrathecal or epidural administration, via said system. Therefore, one of ordinary skill in the art would have been motivated to incorporate said injectable pharmaceutical composition comprising gabapentin, baclofen, midazolam, valproic acid and/or sodium valproate into said therapeutic agent containing reservoir, which is coupled to said implantable osmotic pump, so as to provide for a system of said injectable pharmaceutical composition, as suggested by the Coe '943 publication and the Hochman '601 patent.

With respect to claims 19-27 of the instant application, although the Coe '943 publication does not explicitly teach the instantly claimed invention, the Coe '943 publication does teach that said sterile injectable pharmaceutical composition *may* comprise an anticonvulsant in combination with an analgesic for the treatment of epilepsy and pain ([0006], [0138], [0270], [0368] and [0373]). More specifically, the Coe '943 publication teaches that gabapentin, valproic acid and baclofen are particularly useful in the treatment of epilepsy and pain ([0006], [0138], [0270], [0368] and [0373]). Therefore, it would have been prima facie obvious to one of ordinary skill in the art at the time the instant application was filed to in fact utilize gabapentin in combination with valproic acid and/or

baclofen. One of ordinary skill in the art would have been motivated to combine gabapentin together with valproic acid and/or baclofen within said sterile injectable pharmaceutical composition, so as to obtain a sterile injectable pharmaceutical composition that is particularly useful in the treatment of epilepsy and pain, as suggested by the Coe '943 publication. In addition, although the Coe '943 publication teaches utilizing valproic acid as an anticonvulsant analgesic, the Coe '943 publication does not explicitly teach utilizing the sodium salt of valproic acid, namely sodium valproate (a.k.a., valproate). However, it would have been prima facie obvious to one of ordinary skill in the art at the time the instant application was filed to utilize valproate, as valproate is merely the sodium salt of valproic acid, and one of ordinary skill in the art would reasonably expect that the sodium salt of valproic acid would also exhibit anticonvulsant analgesic activity similar, if not identical, to that of valproic acid. Furthermore, while the Coe '943 publication does not explicitly teach utilizing midazolam and valproate in combination with gabapentin, it would have been prima facie obvious to one of ordinary skill in the art at the time the instant application was filed to modify the injectable pharmaceutical composition of the Coe '943 publication to utilize gabapentin in combination with midazolam and/or valproate, as the Hochman '601 patent explicitly teaches utilizing not only gabapentin, but also midazolam and valproate in the treatment of epilepsy and pain associated with migraine headaches (column 3, lines 19-24; column 6, lines 20-43; column 8, lines 31-42; column 14, lines 42-67; and column 15, lines 1-47). Therefore, it would have been prima facie obvious to one of ordinary skill in the art at the time the instant application was filed to utilize gabapentin in combination with baclofen, midazolam, valproic acid and/or sodium valproate, within said injectable pharmaceutical composition so as to impart desired antiepileptic and analgesic properties to said injectable pharmaceutical composition. One of ordinary skill in the art would have been motivated to

utilize gabapentin in combination with baclofen, midazolam, valproic acid and/or sodium valproate within said injectable pharmaceutical composition so as to obtain an injectable pharmaceutical composition, which is particularly useful in the treatment epilepsy and pain, as suggested by the Hochman '601 patent.

With respect to claims 19-27 of the instant application, although neither the Coe '943 publication nor the Hochman '601 patent explicitly teach the instantly claimed concentrations of gabapentin, valproic acid, sodium valproate, baclofen and midazolam present within said injectable pharmaceutical composition, the Coe '943 publication explicitly teaches that: said gabapentin may be present in an amount from 0.1% by weight to 95% by weight of said pharmaceutical composition ([0373]) and parenterally administered ([0283] and [0370]) in an amount from 10.0 mg/kg/day to 35.0 mg/kg/day ([0315]); said valproic acid may be present in an amount from 0.1% by weight to 95% by weight of said pharmaceutical composition ([0373]) and parenterally administered ([0283] and [0370]) in an amount from 1.0 mg/kg/day to 60.0 mg/kg/day ([0319]); and said baclofen may be present in an amount from 0.1% by weight to 95% by weight of said pharmaceutical composition ([0373]) and parenterally administered ([0283] and [0370]) in an amount from 0.1 mg/kg/day to 0.5 mg/kg/day ([0350]). Furthermore, the Hochman '601 patent teaches that suitable therapeutic dosages of gabapentin, midazolam and valproate are readily obtainable by standard techniques well known to those of ordinary skill in the art (column 14, lines 18-67; and column 15, lines 1-47). It is well within the purview of the skilled artisan to determine the desired optimal workable concentrations of gabapentin, baclofen, midazolam, valproic acid and/or sodium valproate by systematically adjusting the injectable dosage amounts of gabapentin, baclofen, midazolam, valproic acid and/or sodium valproate in a given per unit volume of diluent during the course of routine experimentation. "Where

the general conditions of a claim are disclosed in the prior art, it is not inventive to discover the optimum or workable ranges by routine experimentation.” See *In re Aller*, 105 USPQ 233, 235 (CCPA 1955). “The normal desire of scientists or artisans to improve upon what is already generally known provides the motivation to determine where in a disclosed set of percentage ranges is the optimum combination of percentages.” See *Peterson*, 65 USPQ2d 1379, 1382 (Fed. Cir. 2003).

With respect to claims 8-10 of the instant application, although the Coe ‘943 publication explicitly teaches that said sterile injectable pharmaceutical composition comprises a sterile aqueous isotonic saline solution for parenteral administration ([0283], [0368], [0370] and [0372]), the Coe ‘943 publication does not explicitly teach a specific numerical value of osmolality that is isotonic with cerebrospinal fluid, wherein said sterile injectable pharmaceutical composition further comprises less than 0.9% weight per volume of sodium chloride. However, parenteral administration by definition includes any route of administration (i.e., intracranial, intrathecal or epidural) other than enteral (i.e., oral) administration. Therefore, it would have been *prima facie* obvious to one of ordinary skill in the art at the time the instant application was filed to utilize an appropriate weight per volume of sodium chloride so as to render an sterile injectable pharmaceutical composition comprising a sterile aqueous isotonic saline solution possessing a desired osmolality that is isotonic with cerebrospinal fluid thereby rendering said sterile injectable pharmaceutical composition suitable for parenteral administration via intracranial, intrathecal or epidural injection.

With respect to claims 11-13 and 17 of the instant application, although the Coe ‘943 publication does not explicitly teach a specific pH that is physiologically similar to that of cerebrospinal fluid, the Coe ‘943 publication does teach that said sterile injectable pharmaceutical composition comprises a sterile aqueous isotonic saline solution, which is suitably buffered, if

necessary, for parenteral administration and is readily obtainable by standard techniques well known to those of ordinary skill in the art ([0283], [0368], [0370] and [0372]). Parenteral administration by definition includes any route of administration (i.e., intracranial, intrathecal or epidural) other than enteral (i.e., oral) administration. Therefore, it would have been *prima facie* obvious to one of ordinary skill in the art at the time the instant application was filed to utilize a pH buffer, if necessary, so as to render an injectable pharmaceutical composition comprising a sterile aqueous isotonic saline solution possessing a desired pH suitable for parenteral administration so as to render an sterile injectable pharmaceutical composition comprising a sterile aqueous isotonic saline solution possessing a desired pH that is physiologically similar to that of cerebrospinal fluid thereby rendering said sterile injectable pharmaceutical composition suitable for parenteral administration via intracranial, intrathecal or epidural injection.

Therefore, the claimed invention, as a whole, would have been *prima facie* obvious to one of ordinary skill in the art at the time the invention was made, because each and every element of the claimed invention, as a whole, would have been reasonably suggested by the teachings of the cited prior art references.

2. Claims 8-13 and 17 are rejected under 35 U.S.C. § 103(a) as being unpatentable over U.S. Pre-Grant Patent Application Publication Number 2001/0036943 (hereinafter the Coe '943 publication) in view of U.S. Patent 6,495,601 (hereinafter the Hochman '601 patent) and in further view of U.S. Patent 4,755,388 (hereinafter the Heath '388 patent).

The teachings of the Coe '943 publication in view of the Hochman '601 patent are incorporated herein by reference and are therefore applied in the instant rejection as discussed hereinabove.

With respect to claims 8-10 of the instant application, although the Coe '943 publication explicitly teaches that said sterile injectable pharmaceutical composition comprises a sterile aqueous isotonic saline solution for parenteral administration ([0283], [0368], [0370] and [0372]), the Coe '943 publication does not explicitly teach a specific numerical value of osmolality that is isotonic with cerebrospinal fluid, wherein said sterile injectable pharmaceutical composition further comprises less than 0.9% weight per volume of sodium chloride. However, the Heath '388 patent teaches an aqueous gabapentin drug composition comprising an osmotic modifier, such as an aqueous saline solution (column 3, lines 10-20; and column 5, lines 6-9), whereby said aqueous gabapentin drug composition can be formulated in a manner such that said aqueous gabapentin drug composition has an osmolality from about 250 mOsm/kg to about 350 mOsm/kg, thereby rendering said aqueous gabapentin drug composition isotonic with physiological cerebrospinal fluid. Therefore, it would have been prima facie obvious to one of ordinary skill in the art at the time the instant application was filed to modify the injectable pharmaceutical composition of the Coe '943 publication by incorporating an appropriate weight per volume of sodium chloride (i.e., less than or equal to 0.9% weight per volume of sodium chloride) thereby rendering said aqueous gabapentin drug composition having a specific osmolality from about 250 mOsm/kg to about 350 mOsm/kg, which is isotonic with cerebrospinal fluid, as suggested by the Heath '388 patent, so as to provide for parenteral administration of said injectable pharmaceutical composition via intracranial, intrathecal or epidural administration.

With respect to claims 11-13 and 17 of the instant application, although the Coe '943 publication explicitly teaches that said sterile injectable pharmaceutical composition comprises a sterile aqueous isotonic saline solution, which is suitably buffered, if necessary, for parenteral administration ([0283], [0368], [0370] and [0372]), the Coe '943 publication does not explicitly teach

a specific pH that is physiologically similar to that of cerebrospinal fluid. However, the Heath '388 patent teaches an aqueous gabapentin drug composition comprising a pH buffer (column 3, lines 10-20; and column 5, lines 6-9), whereby said aqueous gabapentin drug composition can be formulated in a manner such that said aqueous gabapentin drug composition has a pH from about 6 to about 9, thereby rendering said aqueous gabapentin drug composition having a pH that is physiologically similar to that of cerebrospinal fluid. Therefore, it would have been prima facie obvious to one of ordinary skill in the art at the time the instant application was filed to modify the injectable pharmaceutical composition of the Coe '943 with a pH buffer, if necessary, so as to impart not only a specific pH from about 6 to about 9, preferably from about 6 to about 8, and more preferably from about 6.5 to about 7.5, which is physiologically similar to that of cerebrospinal fluid, as suggested by the Heath '388 patent, so as to provide for parenteral administration of said injectable pharmaceutical composition via intracranial, intrathecal or epidural administration.

Therefore, the claimed invention, as a whole, would have been prima facie obvious to one of ordinary skill in the art at the time the invention was made, because each and every element of the claimed invention, as a whole, would have been reasonably suggested by the teachings of the cited prior art references.

Conclusion

Claims 29-57 were withdrawn from consideration as being drawn to a non-elected invention.

Claims 1-28 and 58-59 are rejected.


Contact Information

Any inquiry concerning this communication or earlier communications from the Examiner should be directed to David P. Stitzel, Esq. whose telephone number is 571-272-8508. The Examiner can normally be reached on Monday-Friday, from 7:30AM-6:00PM.

If attempts to reach the Examiner by telephone are unsuccessful, the Examiner's supervisor, Sreenivasan Padmanabhan can be reached at 571-272-0629. The central fax number for the USPTO is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published patent applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished patent applications is only available through Private PAIR. For more information about the PAIR system, please see <http://pair-direct.uspto.gov>. Should you have questions about acquiring access to the Private PAIR system, please contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

David P. Stitzel, Esq.


SREENI PADMANABHAN
SUPERVISORY PATENT EXAMINER